Approval · Notice of Compliance 26223 · 2021
ARAZLO: Notice of Compliance 26223
Issued July 8, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26223
- Date
- July 8, 2021
- Company
- Bausch Health, Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ARAZLO | 02517868 | Marketed |
Medicinal ingredients
- TAZAROTENE 0.045 PER